Search results
Results from the WOW.Com Content Network
Sitagliptin, sold under the brand name Januvia among others, is an anti-diabetic medication used to treat type 2 diabetes. [8] In the United Kingdom it is listed as less preferred than metformin or a sulfonylurea. [9] It is taken by mouth. [8] It is also available in the fixed-dose combination medication sitagliptin/metformin (Janumet, Janumet ...
Clinical researches have shown that sitagliptin and vildagliptin do not have the side effects that tend to follow type 2 diabetes treatment, e.g. weight gain and hyperglycemia, but however, other side effects have been observed, including upper respiratory tract infections, sore throat and diarrhea. [5]
In 2013, Januvia was the second largest selling diabetes drug worldwide. [11] Januvia is commonly paired with the generic anti-diabetes drug metformin. It has been popular due in part because unlike many other diabetes drugs, it causes little or no weight gain and is not associated with hypoglycemic episodes.
Merck Welcomes Independent Review of the Safety Profile of JANUVIA ® (sitagliptin) and Other Diabetes Medicines WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- Merck, known as MSD outside the United ...
For the last several years, Merck has been able to ride the success of its leading type 2 diabetes franchise Januvia/Janumet, which generated $5.75 billion in sales last year and represented more ...
Diabetes drug Januvia has been a boon for Merck in recent years, and its massive year-over-year growth was one way the company was able to offset the huge losses incurred by Singulair's recent ...
In the United States, sitagliptin/metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. [5] [6]In the European Union, sitagliptin/metformin is indicated as an adjunct to diet and exercise to improve glycemic control in people with type 2 diabetes; in combination with a sulfonylurea as an adjunct to diet and exercise "in people ...
The Food and Drug Administration warned Thursday that diabetes drugs might be elevating the rate of pancreatic cancer. Investors shouldn't be surprised. Nor particularly worried. We've known for ...